Pricing Log in Create free account

Cellectis S.A. (CLLS) vs Pelthos Therapeutics Inc. (PTHS)

Cellectis S.A. and Pelthos Therapeutics Inc. are both Biotechnology companies. Cellectis S.A. and Pelthos Therapeutics Inc. are of similar size ($79.9M and $77.6M). Cellectis S.A. has the higher net margin (−102.3% vs −199.5%) and the higher return on invested capital (0.00% vs −82.3%). Across the 15 metrics below, Cellectis S.A. leads on 10 and Pelthos Therapeutics Inc. on 5.

Valuation

Metric CLLS PTHS Biotechnology median
P/E n/m n/m 8.50
P/S 1.64 1.65 9.71
P/B 2.55 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.18 2.75 9.21
Earnings yield (62.89%) (142.54%) (33.15%)
Free cash flow yield (44.14%) (59.72%) (25.50%)

Profitability

Metric CLLS PTHS Biotechnology median
Gross margin 100.00% 78.59% 65.16%
Operating margin (90.88%) (133.42%) 0.00%
Net margin (102.34%) (199.50%) 0.00%
Free cash flow margin (68.63%) (98.37%) 0.00%
Return on equity (94.54%) 2,161.07% (56.36%)
Return on assets (21.02%) (125.04%) (48.04%)
Return on invested capital 0.00% (82.34%) 0.00%

Growth

Metric CLLS PTHS Biotechnology median
Revenue growth (TTM) 0.61% — 6.02%
EPS growth (last fiscal year) (63.41%) (61.12%) 30.26%
Revenue growth, 5-year CAGR (0.70%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CLLS PTHS Biotechnology median
Debt to equity 1.79 (46.58) 0.00
Current ratio 1.37 1.98 4.72
Net debt to EBITDA 9.54 (0.45) 0.96

Dividend

Metric CLLS PTHS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLLS PTHS Biotechnology median
Market cap 79.92m 77.57m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack